Science
Pipeline Overview
Explore the 19 medicines in Junshi’s English pipeline chart, with additional records for selected clinical studies and U.S. authorization.
Sources reviewed 16 November 2026. Corporate stages group development by medicine. Registered studies and authorizations identify a specific indication or treatment setting.
Pipeline Chart
JS212EGFR × HER3 ADC TumorsCorporate program Phase I/II
Oncology · Junshi’s corporate chart places JS212 in the Phase I/II group. This grouping covers early clinical development.
View sourceJS213PD-1 × IL-2 Advanced malignant tumorsCorporate program Phase I/II
Oncology · Junshi’s corporate chart places JS213 in the Phase I/II group. This grouping covers early clinical development.
View sourceJS111EGFR exon 20 Non-small cell lung cancerCorporate program Phase I/II
Oncology · Junshi’s corporate chart places JS111 in the Phase I/II group. This grouping covers early clinical development.
View sourceJS214VEGF × TGF-β TumorsCorporate program Phase I/II
Oncology · Junshi’s corporate chart places JS214 in the Phase I/II group. This grouping covers early clinical development.
View sourceJS110XPO1 Endometrial cancerCorporate program Phase I/II
Oncology · Junshi’s corporate chart places JS110 in the Phase I/II group. This grouping covers early clinical development.
View sourceJS015DKK1 TumorsCorporate program Phase I/II
Oncology · Junshi’s corporate chart places JS015 in the Phase I/II group. This grouping covers early clinical development.
View sourceJT002Small nucleic acid immunomodulator Seasonal allergic rhinitisCorporate program Phase I/II
Autoimmune · Junshi’s corporate chart places JT002 in the Phase I/II group. This grouping covers early clinical development.
View sourceJS207PD-1 × VEGF TumorsCorporate program Phase III
Oncology · Junshi’s corporate chart places JS207 in the Phase III group.
View sourceJS203CD20 × CD3 TumorsCorporate program Phase III
Oncology · Junshi’s corporate chart places JS203 in the Phase III group.
View sourceJS007CTLA-4 Lung cancer and melanomaCorporate program Phase III
Oncology · Junshi’s corporate chart places JS007 in the Phase III group.
View sourceTifcemalimabBTLA Lung cancer and lymphomaCorporate program Phase III
Oncology · Junshi’s corporate chart places Tifcemalimab in the Phase III group.
View sourceRoconkibartIL-17A Psoriasis and spondylitisCorporate program Phase III
Autoimmune · Junshi’s corporate chart places Roconkibart in the Phase III group.
View sourceJS001scPD-1 TumorsCorporate program Phase III
Oncology · Junshi’s corporate chart places JS001sc in the Phase III group.
View sourceJS105PI3K-α Gynecological tumorsCorporate program Phase III
Oncology · Junshi’s corporate chart places JS105 in the Phase III group.
View sourceJS107Claudin 18.2 ADC Gastrointestinal cancerCorporate program Phase III
Oncology · Junshi’s corporate chart places JS107 in the Phase III group.
View sourceToripalimabPD-1 Oncology indicationsCorporate program Marketed
Oncology · Junshi includes Toripalimab in the marketed group. Approved indications vary by jurisdiction.
View sourceAdalimumabTNF-α Rheumatoid arthritis and other approved indicationsCorporate program Marketed
Autoimmune · Junshi includes Adalimumab in the marketed group. Approved indications vary by jurisdiction.
View sourceDeuremidevir hydrobromide (VV116)RdRp COVID-19Corporate program Marketed
Infectious diseases · Junshi includes Deuremidevir hydrobromide (VV116) in the marketed group. Approved indications vary by jurisdiction.
View sourceOngericimabPCSK9 Primary hypercholesterolemia and mixed dyslipidemiaCorporate program Marketed
Metabolic · Junshi includes Ongericimab in the marketed group. Approved indications vary by jurisdiction.
View sourceJS212EGFR × HER3 ADC Recurrent or metastatic triple-negative breast cancerRegistered study Phase II
Oncology · JS212 alone or in combination is being studied in a Phase II trial.
View sourceJS212EGFR × HER3 ADC Advanced malignant solid tumorsRegistered study Phase I/II
Oncology · An early-phase study evaluates JS212 in participants with advanced malignant solid tumors.
View sourceJS203CD20 × CD3 Relapsed or refractory diffuse large B-cell lymphomaRegistered study Phase III
Oncology · This Phase III study compares JS203 plus chemotherapy with rituximab plus chemotherapy.
View sourceTifcemalimabBTLA Limited-stage small-cell lung cancerRegistered study Phase III
Oncology · A Phase III study evaluates consolidation treatment with toripalimab alone or with tifcemalimab after chemoradiotherapy.
View sourceToripalimab-tpziPD-1 Nasopharyngeal carcinomaU.S. authorization Approved
Oncology · The U.S. FDA approved toripalimab-tpzi for defined adult nasopharyngeal carcinoma indications, both in combination with chemotherapy and as a single agent in specified settings.
View sourceNo matches. Change a filter or reset the selection.
Program Details
The company’s product directory lists 37 additional entries across four therapeutic areas. The English stage chart does not assign these entries a phase.
Oncology (29)
- JS211
- JS209
- JS208
- JS206
- JS205
- JS123
- JS122
- JS121
- JS120
- JS115
- JS114
- JS104
- JS018
- JS013
- JS011
- JS201
- JS125
- JS116
- JS113
- JS112
- JS108
- JS101
- JS019
- JS014
- JS012
- JS009 (TAB009)
- JS006 (TAB006)
- JS003
- Bevacizumab (JS501)
Autoimmune (1)
- UBP1213sc
Metabolic (3)
- JS008
- JS401
- JS103
Infectious diseases (4)
- JT109
- JT003 (VV993)
- JS026
- Etesevimab
Bevacizumab (JS501), a VEGF-targeted program, appears in the oncology directory. The company reported Phase III on 28 March 2024. See the dated investor disclosure